Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Therapeutic human papillomavirus vaccines in head and neck cancer: A systematic review of current clinical trials

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effectiveness of varying number of doses and timing between doses of quadrivalent HPV vaccine against severe cervical lesions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Ad hominem attacks on vaccine safety researchers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Dynamic soft tissue changes in the orbit after a blowout fracture

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Reliability and validity of The Danish pediatric voice handicap index

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVES: This systematic review provides an overview of the current clinical trials investigating therapeutic vaccines for HPV+ head and neck cancer and discusses the future directions of therapeutic vaccine therapy.

MATERIALS AND METHODS: A systematic search was conducted in PubMed, EMBASE, Cochrane and clinicaltrials.gov for clinical trials involving therapeutic vaccines. We included studies initiated between 2000 and 2018 with patients diagnosed with HPV+ head and neck cancer and extracted data concerning type of vaccine therapy, adverse events, immunogenicity and clinical outcome measures (e.g. tumour response, progression-free survival and overall survival).

RESULTS: We identified 11 studies (n = 376 patients) initiated between year 2005 and 2017. Four studies (n = 34) presented preliminary results in patients with incurable, recurrent loco-regional or distant metastatic disease indicating a positive immune response with 74% (n = 25/34 patients) having elevated antibody levels, IFN-γ and/or T-cell response. Five studies presented data on the vaccines' safety profile, demonstrating predominantly grade 1 and 2 toxicity. Three studies evaluated the clinical outcome - one study showed no complete or partial response, one study demonstrated stable disease as the best tumour response in 64% (n = 9/14 patients) and one study showed a 33% overall response rate: one patient with a complete response and seven patients with a partial response.

CONCLUSIONS: Treatment with therapeutic vaccines is a promising and seemingly safe strategy for patients with HPV+ head and neck cancer. However, there are not enough data to draw any further conclusions and clinical outcome measures and tumour responses to the vaccines are still missing.

OriginalsprogEngelsk
TidsskriftVaccine
Vol/bind36
Udgave nummer45
Sider (fra-til)6594-6605
Antal sider12
ISSN0264-410X
DOI
StatusUdgivet - 29 okt. 2018

ID: 56133083